Pacific Biosciences Of California (PACB) Accumulated Depreciation & Amortization (2012 - 2025)

Pacific Biosciences Of California has reported Accumulated Depreciation & Amortization for 14 years, with the latest figure at $92.5 million in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Depreciation & Amortization rose 12.84% year-over-year to $92.5 million; the trailing twelve-month figure through Dec 2025 stood at $92.5 million (up 12.84% YoY), and the FY2025 full-year result was $92.5 million, up 12.84% from the prior year.
• Accumulated Depreciation & Amortization for Q4 2025 stood at $92.5 million, up from $81.9 million in the prior quarter.
• The five-year high for Accumulated Depreciation & Amortization was $92.5 million in Q4 2025, with the low at $56.3 million in Q4 2021.
• Average Accumulated Depreciation & Amortization over 5 years is $74.1 million, with a median of $74.8 million recorded in 2023.
• Year-over-year, Accumulated Depreciation & Amortization grew 15.46% in 2022 and grew 9.56% in 2024.
• Tracing PACB's Accumulated Depreciation & Amortization over 5 years: stood at $56.3 million in 2021, then advanced by 15.46% to $65.0 million in 2022, then advanced by 15.09% to $74.8 million in 2023, then climbed by 9.56% to $81.9 million in 2024, then gained by 12.84% to $92.5 million in 2025.
• The last three Accumulated Depreciation & Amortization figures came in at $92.5 million (Q4 2025), $81.9 million (Q4 2024), and $74.8 million (Q4 2023), per Business Quant data.

Peer Comparison